7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir

Angew Chem Int Ed Engl. 2018 Jun 11;57(24):7181-7185. doi: 10.1002/anie.201802256. Epub 2018 May 14.

Abstract

Dolutegravir (DTG), an important active pharmaceutical ingredient (API) used in combination therapy for the treatment of HIV, has been synthesized in continuous flow. By adapting the reported GlaxoSmithKline process chemistry batch route for Cabotegravir, DTG was produced in 4.5 h in sequential flow operations from commercially available materials. Key features of the synthesis include rapid manufacturing time for pyridone formation, one-step direct amidation of a functionalized pyridone, and telescoping of multiple steps to avoid isolation of intermediates and enable for greater throughput.

Keywords: HIV; amidation; continuous flow; multistep synthesis; pyridone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / chemical synthesis
  • Amides / chemistry
  • Combinatorial Chemistry Techniques / economics
  • Combinatorial Chemistry Techniques / methods
  • HIV Infections / drug therapy
  • HIV Integrase Inhibitors / chemical synthesis*
  • HIV Integrase Inhibitors / chemistry
  • Heterocyclic Compounds, 3-Ring / chemical synthesis*
  • Heterocyclic Compounds, 3-Ring / chemistry
  • Humans
  • Oxazines
  • Piperazines
  • Pyridones / chemical synthesis
  • Pyridones / chemistry
  • Time Factors

Substances

  • Amides
  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir